Report cover image

Anti-CD30 Therapies - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 60 Pages
SKU # DEL18679248

Description

Anti-CD30 Therapies - Pipeline Insight, 2024



DelveInsight’s, “Anti-CD30 Therapies - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anti-CD30 Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Anti-CD30 Therapies Understanding

Anti-CD30 Therapies: Overview

CD30 (also known as TNFRSF8) is a 120-kD transmembrane protein of the tumor necrosis factor family. The protein is comprised of an extracellular domain, a transmembrane region and a cytoplasmic domain. The majority of antibodies against human CD30 recognize epitopes within the extracellular domain. CD30 signaling regulates peripheral T-cell responses, controlling T-cell survival, and downregulating cytolytic capacity. CD30 is expressed on activated T cells, NK cells, and B cells. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma and Hodgkin lymphoma, among others. Studies have also shown a role of CD30 as a T-cell costimulatory molecule involved in Th1, Th2, and Th17 immune responses. The restriction of CD30 expression on normal cells makes it an attractive candidate for targeted therapy. In studies, anti-CD30 antibodies alone display therapeutic efficacy, the newer agents markedly enhance antibody effectiveness through their conjugation with various cytotoxic agents. Hence, CD30 can serve both as a diagnostic marker for lymphocyte malignancies and as a target for therapy.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Anti-CD30 Therapies R&D. The therapies under development are focused on novel approaches for Anti-CD30 Therapies.
Anti-CD30 Therapies Emerging Drugs Chapters

This segment of the Anti-CD30 Therapies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Anti-CD30 Therapies Emerging Drugs
  • Brentuximab vedotin - Seagen/Takeda
Brentuximab Vedotin (ADCETRIS) is an antibody-drug conjugate (ADC) therapy developed by Seagen and its Takeda Oncology. The ABC contains an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics’ proprietary technology. This linker system makes the molecule stable in the bloodstream but to release MMAE upon internalization into CD30-expressing cells. Under the terms of the collaboration agreement, Seattle Genetics has U.S. and Canadian commercialization rights and Takeda has rights to commercialize ADCETRIS in the rest of the world.
  • AFM13: Affimed
AFM13 is a tetravalent bispecific chimeric (anti-human CD30 x anti-human CD16A) recombinant antibody construct which is being developed to treat CD30-positive malignancies. The molecule is currently in Phase II clinical evaluation for the treatment of Relapsed/Refractory CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides.

Further product details are provided in the report……..

Anti-CD30 Therapies: Therapeutic Assessment

This segment of the report provides insights about the different Anti-CD30 Therapies drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players working on Anti-CD30 Therapies
There are approx. 10+ key companies which are developing the Anti-CD30 Therapies. The companies which have their Anti-CD30 Therapies drug candidates in the most advanced stage, i.e. Phase III include, Seagen/Takeda.
  • Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Anti-CD30 Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Anti-CD30 Therapies: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Anti-CD30 Therapies therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD30 Therapies drugs.

Anti-CD30 Therapies Report Insights
  • Anti-CD30 Therapies Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Anti-CD30 Therapies Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing Anti-CD30 Therapies drugs?
  • How many Anti-CD30 Therapies drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Anti-CD30 Therapies?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anti-CD30 Therapies therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Anti-CD30 Therapies and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Seagen
  • Takeda Oncology
  • Cellular Biomedicine Group
  • Wuhan Bio Raid Biotechnology
  • Affimed
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.
  • Tessa Therapeutics
Key Products
  • Brentuximab vedotin
  • CART 30
  • Anti-CD30 chimeric antigen receptor T-cell therapy
  • AFM13
  • F0002-ADC
  • TT 11
  • SGN-CD30C

Table of Contents

60 Pages
Introduction
Executive Summary
Anti-CD30 Therapies: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Anti-CD30 Therapies – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Anti-CD30 Therapies companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Anti-CD30 Therapies Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Brentuximab vedotin: Seagen/Takeda Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
AFM13: Affimed
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Anti-CD30 chimeric antigen receptor T-cell therapy: Wuhan Bio Raid Biotechnology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Anti-CD30 Therapies Key Companies
Anti-CD30 Therapies Key Products
Anti-CD30 Therapies- Unmet Needs
Anti-CD30 Therapies- Market Drivers and Barriers
Anti-CD30 Therapies- Future Perspectives and Conclusion
Anti-CD30 Therapies Analyst Views
Anti-CD30 Therapies Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us